Bluebird Bio Inc. (BLUE) Given a $95.00 Price Target by Piper Jaffray Cos. Analysts
Bluebird Bio Inc. (NASDAQ:BLUE) has been given a $95.00 price target by equities researchers at Piper Jaffray Cos. in a note issued to investors on Thursday. The firm currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price objective indicates a potential upside of 44.93% from the stock’s current price.
A number of other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Bluebird Bio from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Wedbush reaffirmed an “outperform” rating and issued a $117.00 price target on shares of Bluebird Bio in a research report on Monday, October 3rd. Jefferies Group reaffirmed a “buy” rating and issued a $80.00 price target on shares of Bluebird Bio in a research report on Friday, September 30th. Maxim Group set a $100.00 price target on Bluebird Bio and gave the stock a “buy” rating in a research report on Thursday, September 29th. Finally, Roth Capital began coverage on Bluebird Bio in a research report on Thursday, September 22nd. They issued a “buy” rating and a $87.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.25.
Bluebird Bio (NASDAQ:BLUE) traded up 0.08% during midday trading on Thursday, reaching $65.60. The company’s stock had a trading volume of 1,182,587 shares. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70. The firm’s market capitalization is $2.44 billion. The firm has a 50 day moving average price of $63.09 and a 200 day moving average price of $50.71.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/bluebird-bio-inc-blue-given-a-95-00-price-target-by-piper-jaffray-cos-analysts.html
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The company earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same period in the previous year, the business posted ($1.57) earnings per share. The firm’s revenue was down 68.6% on a year-over-year basis. On average, analysts predict that Bluebird Bio will post ($6.19) EPS for the current year.
In other Bluebird Bio news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $45.08, for a total value of $45,080.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $477,848. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eric Sullivan sold 2,807 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $45.04, for a total value of $126,427.28. Following the completion of the transaction, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The disclosure for this sale can be found here. 3.50% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Cupps Capital Management LLC acquired a new position in Bluebird Bio during the third quarter worth approximately $1,824,000. Gradient Investments LLC acquired a new position in Bluebird Bio during the third quarter worth approximately $333,000. First Mercantile Trust Co. acquired a new position in Bluebird Bio during the third quarter worth approximately $129,000. BNP Paribas Arbitrage SA raised its position in Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock worth $209,000 after buying an additional 1,619 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in Bluebird Bio by 43.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 145,569 shares of the company’s stock worth $6,302,000 after buying an additional 44,048 shares in the last quarter.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.